260 related articles for article (PubMed ID: 15317038)
1. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Gearry RB; Barclay ML; Burt MJ; Collett JA; Chapman BA
Pharmacoepidemiol Drug Saf; 2004 Aug; 13(8):563-7. PubMed ID: 15317038
[TBL] [Abstract][Full Text] [Related]
2. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
3. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
[TBL] [Abstract][Full Text] [Related]
4. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID
Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235
[TBL] [Abstract][Full Text] [Related]
5. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.
Hindorf U; Lindqvist M; Hildebrand H; Fagerberg U; Almer S
Aliment Pharmacol Ther; 2006 Jul; 24(2):331-42. PubMed ID: 16842460
[TBL] [Abstract][Full Text] [Related]
6. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
López-Martín C; Chaparro M; Espinosa L; Bejerano A; Maté J; Gisbert JP
Gastroenterol Hepatol; 2011; 34(6):385-92. PubMed ID: 21616565
[TBL] [Abstract][Full Text] [Related]
7. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease.
Daperno M; Sostegni R; Canaparo R; Serpe L; Lavagna A; Crocellà L; Castagno F; Vernetto A; Rigazio C; Ercole E; D'Antico S; Pera A; Zara G; Rocca R
Aliment Pharmacol Ther; 2009 Oct; 30(8):843-53. PubMed ID: 19650826
[TBL] [Abstract][Full Text] [Related]
8. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review.
Gisbert JP; Gomollón F
Am J Gastroenterol; 2008 Jul; 103(7):1783-800. PubMed ID: 18557712
[TBL] [Abstract][Full Text] [Related]
9. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients.
Gisbert JP; Niño P; Rodrigo L; Cara C; Guijarro LG
Am J Gastroenterol; 2006 Dec; 101(12):2769-76. PubMed ID: 17026564
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease.
Cao Q; Zhu Q; Shang Y; Gao M; Si J
Digestion; 2009; 79(1):58-63. PubMed ID: 19252404
[TBL] [Abstract][Full Text] [Related]
11. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Gearry RB; Barclay ML
J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
[TBL] [Abstract][Full Text] [Related]
12. Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients.
Gazouli M; Pachoula I; Panayotou I; Mantzaris G; Syriopoulou VP; Goutas N; Vlachodimitropoulos D; Anagnou NP; Roma-Giannikou E
J Clin Pharm Ther; 2010 Feb; 35(1):93-7. PubMed ID: 20175817
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of azathioprine in the treatment of inflammatory bowel disease.
Martínez F; Nos P; Pastor M; Garrigues V; Ponce J
Rev Esp Enferm Dig; 2001 Dec; 93(12):769-78. PubMed ID: 11995359
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of thiopurine therapy in paediatric IBD patients.
De Ridder L; Van Dieren JM; Van Deventer HJ; Stokkers PC; Van der Woude JC; Van Vuuren AJ; Benninga MA; Escher JC; Hommes DW
Aliment Pharmacol Ther; 2006 Apr; 23(8):1137-41. PubMed ID: 16611274
[TBL] [Abstract][Full Text] [Related]
15. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease.
Ananthakrishnan AN; Attila T; Otterson MF; Lipchik RJ; Massey BT; Komorowski RA; Binion DG
J Clin Gastroenterol; 2007 Aug; 41(7):682-8. PubMed ID: 17667053
[TBL] [Abstract][Full Text] [Related]
16. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
Hindorf U; Lyrenäs E; Nilsson A; Schmiegelow K
Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
[TBL] [Abstract][Full Text] [Related]
17. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease.
Hindorf U; Johansson M; Eriksson A; Kvifors E; Almer SH
Aliment Pharmacol Ther; 2009 Mar; 29(6):654-61. PubMed ID: 19183142
[TBL] [Abstract][Full Text] [Related]
18. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease.
Disanti W; Rajapakse RO; Korelitz BI; Panagopoulos G; Bratcher J
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1025-9. PubMed ID: 16765651
[TBL] [Abstract][Full Text] [Related]
19. Azathioprine in inflammatory bowel disease, a safe alternative?
Tanis AA
Mediators Inflamm; 1998; 7(3):141-4. PubMed ID: 9705598
[TBL] [Abstract][Full Text] [Related]
20. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
